Ask Warren

HLB

028300 · KOSDAQ · ₩028300 · HLB

₩40,000▲ ₩300 (0.76%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −18.37%
Market cap
₩5.3T
Enterprise value
₩5.6T
P/E
—
P/B
15.5×
Dividend yield
0.0%
ROE
−62.0%
Net margin
−219.1%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−42.2% from the high

₩24,150Today: ₩38,800 – ₩40,350₩69,200

Returns

  • 1W−3.8%
  • 1M−3.4%
  • 3M+30.7%
  • 6M−34.2%
  • YTD−21.3%
  • 1Y−18.4%
Volume today
735,543
0.8× the 20-day average
Traded today
₩30B
Listed shares
133,280,647
EPS (12 months)
−₩1,602
Earnings yield −4.0%
SellBuy
AI research · Update noteHLB Outlines Group Mid-to-Long-Term Strategy After FDA Approval News; Financials UnchangedThe event adds a clearer statement of management ambitions and expectations for an FDA decision, but nothing that is quantified or confirmed in the filings.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

32Quiet
  • BuzzQuietBuzz 32 of 100 (50 is a normal day for this stock).
  • SentimentPositiveNews: Headlines report a sharp after-hours share price rise, with one routine event story. Community: 0 bullish, 0 bearish posts this week.
  • MomentumFlat-0.4% over the last month; the price is below its 20-day average.
  • News impactSome8 news items and filings in two weeks; 0 rated high impact, 1 medium.

Signals describe activity, not recommendations. Not financial advice.

Knock-on effects

[BioS] HLB, After FDA Approval of 'Rifitu,' Announces Group Mid-to-Long-Term Strategy

HLB Life ScienceMoves with HLB (corr 0.90); moved with HLB on 17 of its 18 biggest days

HLB PharmaceuticalMoves with HLB (corr 0.87); moved with HLB on 15 of its 16 biggest days

News about other companies that has, in the past, moved this stock too. Evidence-based, not a prediction.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 29: sell ₩1.6B at the close (3.0% of 20-day average trading value)

Sep 30Last 20 trading days (% of average trading value)Oct 29

On its 20 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 9.3% of trading value and pointed the same way 13 of 20 times.

  • 2× KODEX KOSDAQ150 Leverage −₩1.1B
  • -1× KODEX KOSDAQ150 Futures Inverse −₩273M
  • 2× TIGER KOSDAQ150 Leverage −₩136M
  • 2× RISE KOSDAQ150 Futures Leverage −₩52M
  • -1× TIGER KOSDAQ150 Futures Inverse −₩9M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 11 funds.

Estimated from the funds' index or underlying stock.

Futures and options

All stock futures →

Futures (2026-11): 39,900

Basis −0.25% · implied rate −7.0%

Open interest 18,566 contracts

Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.

HLB stock overview

HLB (HLB, KRX: 028300) is listed on KOSDAQ, in the Biotech & Pharma sector. HLB Inc. Its shares closed at ₩40,000 on Oct 30, 2026, up 0.76% on the day, giving it a market value of ₩5.3T.

Key facts

Market cap
₩5.3T
Sector
Biotech & Pharma
Latest price change
+0.76%
As of
Oct 30, 2026
Main business
HLB Inc.

Quick answers about HLB

What does HLB do?
HLB Inc. , which is involved in new drug development. The excerpt provided is primarily the audit report and financial statements, which do not contain a full business overview of the company's products, customers, or operating regions, so this description is limited to what the reported items indicate.
What is the market cap of HLB?
The market capitalisation of HLB was ₩5.3T at the close on Oct 30, 2026.
Who are the largest shareholders of HLB?
According to the latest official filings, the largest reported holders are Jin Yang-gon (10.01%, as of Aug 20, 2026); Samsung Asset Management (4.09%, as of May 29, 2026); BlackRockFundAdvisors (3.37%, as of Sep 7, 2026).
When is the next earnings report from HLB?
Korean companies rarely announce results dates in advance. Based on when HLB filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own HLB?
Yes. The National Pension Service held 1.16% of HLB shares as of Dec 31, 2025.

Company profile

HLB Inc. and its subsidiaries operate in the Korean pharmaceutical and biotech sector, with a portfolio that includes investments in and goodwill tied to subsidiaries such as Elevar Therapeutics, Inc., which is involved in new drug development. The excerpt provided is primarily the audit report and financial statements, which do not contain a full business overview of the company's products, customers, or operating regions, so this description is limited to what the reported items indicate.

Written by AI from the company's latest annual report.

Korean name
HLB
Sector
Biotech & Pharma
Themes
Biotech (new drugs)Pharmaceuticals
CEO
김홍철
Founded
Oct 1985
Listed
Jul 1996
Listed shares
133,280,647
Fiscal year ends
Month 12
Website
hlbbio.co.kr

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: HLB / 028300 / KRX:028300

Source: KRX statistical information